ARCHIVES

Congress Insists On No Downward Negotiations; NCI May Drop 2000 To 300 Grants In FY 1991

This article is from The Cancer Letter archive.

Vol. 16 No. 43 | November 9, 1990

Download PDF Visit The Full Archive

Related Articles

Turmoil in Texas: SEC Issues Subpoena to AVEO on Tivozanib

July 12, 2013

Selumetinib Plus Docetaxel Effective in KRAS-Mutant Disease

January 25, 2013

Funding Opportunities.

May 10, 2002

FDA, NCI Remain At Odds Over Drug approval Guidelines Despite Reconciliation Discussion

October 9, 1987

Grants & Contracts: NCI Workshop Informs Historically Black Institutions About Funding Process

October 10, 1997

AACR Urges FDA to Regulate High Risk Lab-Developed Tests

September 12, 2014